A 38-year-old man presents with a 2-month history of purple, pruritic papules on his wrists and lower legs with a characteristic reticular pattern. Dermoscopy shows Wickham's striae. Biopsy confirms lichen planus. He denies oral or genital involvement. The lesions are mildly symptomatic but not significantly affecting his quality of life. What is the most appropriate next step in management?

Explanation

## Management of Cutaneous Lichen Planus — Mild to Moderate Disease **Key Point:** Mild cutaneous lichen planus with low symptom burden does not require immediate pharmacological intervention; observation with supportive care and judicious use of topical corticosteroids is appropriate. ### Stepwise Approach to Cutaneous LP ```mermaid flowchart TD A[Confirmed Cutaneous LP]:::outcome --> B{Symptom severity & extent?}:::decision B -->|Mild, localized| C[Reassurance + emollients]:::action C --> D{Symptoms persist or worsen?}:::decision D -->|No| E[Observation, review at 3-6 months]:::action D -->|Yes| F[Topical corticosteroids]:::action B -->|Moderate-severe| G[Topical corticosteroids ± intralesional]:::action B -->|Extensive/refractory| H[Systemic therapy or phototherapy]:::action F --> I{Response adequate?}:::decision I -->|Yes| E I -->|No| H ``` **High-Yield:** Cutaneous LP has a variable course; spontaneous remission occurs in 50–60% of patients over 5–10 years. Mild disease does not warrant aggressive initial treatment. ### Treatment Hierarchy for Cutaneous LP | Severity | First-Line | Second-Line | Third-Line | |----------|-----------|------------|----------| | Mild (asymptomatic/minimally symptomatic) | Observation + emollients | Topical corticosteroids | Intralesional corticosteroids | | Moderate (pruritic, localized) | Topical corticosteroids (Class III–IV) | Intralesional corticosteroids | Phototherapy | | Severe/extensive | Topical corticosteroids + phototherapy | Systemic corticosteroids (short course) | Retinoids, methotrexate | **Clinical Pearl:** The patient's lesions are mildly symptomatic and localized; aggressive treatment risks unnecessary side effects. Topical corticosteroids are reserved for breakthrough symptoms. **Warning:** Do not initiate systemic corticosteroids for mild cutaneous disease—this is overtreatment and exposes the patient to significant adverse effects (hyperglycemia, immunosuppression, osteoporosis) for a self-limited condition. **Tip:** Always ask about symptom impact on quality of life. If the patient is not bothered, observation is justified; if pruritus is significant, topical steroids are added. [cite:Dermatology by Bolognia 4e Ch 15]